DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

Information source: Sanofi
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: warfarin sodium (Drug); mipomersen sodium; warfarin sodium (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Genzyme, a Sanofi Company

Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Genzyme, a Sanofi Company


The purpose of this study is to assess how blood clotting and thinning time is effected when a single dose of warfarin is given alone and when a single dose of warfarin is given with mipomersen; to assess the blood levels of a single dose of warfarin, a single dose of mipomersen, and a single dose of warfarin when given with mipomersen; and to assess the safety of mipomersen when given with or without warfarin.

Clinical Details

Official title: A Drug-Drug Interaction Study to Assess the Effects of Multiple Doses of Mipomersen (200 mg SC) on Single-Dose Warfarin (25 mg) Pharmacodynamics and Pharmacokinetics in Healthy Adult Subjects

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Area under the effect curve (AUC), for INR (international normalized ratio), PT (prothrombin time), and aPTT (activated partial thromboplastin time)

Maximal Value (MAX) for INR, PT and aPTT

Time of maximal effect (Tmax) for INR, PT, and aPTT

Secondary outcome:

Warfarin Plasma Pharmacokinetic parameters (AUC 0-t, AUC 0-inf, Maximum Concentration (Cmax))

Mipomersen Plasma Pharmacokinetic parameters (AUC0-t, AUC0-inf, Cmax)

Incidence of treatment-emergent Adverse Events

Detailed description: This will be a Phase 1, open-label, single-sequence, 2-period, crossover study to determine the effect of multiple doses of mipomersen (200 mg SC given every other day for a total of 4 doses) on the PD and PK of warfarin and to evaluate the PK of mipomersen when administered

alone and in combination with warfarin. Subjects will be admitted to the clinic on Day - 1

until discharge from the clinic on Day 18 and return for outpatient visits on Days 19, 20, and 78. All subjects will receive a single 25-mg oral dose of warfarin given alone on Day 1 (designated the reference treatment). All subjects will then receive 200-mg SC doses of mipomersen given every other day on Days 8, 10, 12, and 14 (total of 800 mg mipomersen) with a single 25-mg oral dose of warfarin also given on Day 14 (combination designated the test treatment).


Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Both.


Inclusion Criteria:

- Written informed consent before any study-related procedure is performed.

- Body mass index (BMI) between 18 and 32 kg/m2, inclusive.

- No clinically significant abnormalities based on medical history, laboratory

assessments, vital sign, 12-lead electrocardiogram (ECG) results, and physical examination.

- Subjects willing and able to follow a prescribed diet.

- Subjects have not consumed nicotine or nicotine-containing products for at least 6

months before Screening.

- Subjects are nonpregnant and nonlactating, surgically sterile, postmenopausal,

abstinent, or the subject or partner is willing to use a reliable method of contraception during the study and for 5 months after mipomersen dosing. Exclusion Criteria:

- Poor metabolizer of warfarin as determined by CYP2C9 genotype testing.

- Clinically significant PT, aPTT, INR, protein C, protein S, or platelet count results

or hematuria.

- Abnormal prolongation of skin bleeding time or a personal or family history of

coagulation or bleeding disorders, vascular malformations including aneurysms, or venous thromboembolism.

- Active or recurring clinically significant cardiovascular, pulmonary, renal,

endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease.

- Active malignancy of any type other than nonmelanomatous skin malignancies.

- Use of any prescribed or over-the-counter concomitant medications within 14 days

before the first dose of investigational product without approval of the Investigator and Sponsor.

- Positive test result for drugs of abuse, alcohol, or cotinine or history of alcohol

abuse or drug addiction.

- Positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or


Locations and Contacts

PPD Development, LP, Austin, Texas, United States
Additional Information

Starting date: May 2010
Last updated: March 19, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017